Buying guide · Cost / review / worth it
Full-body scans sell peace of mind. Sometimes they deliver it. Sometimes they hand you an incidental finding with a scary name and a follow-up bill. The rational buyer prices both outcomes before booking.
Neko is the best-priced low-radiation baseline, Prenuvo is the dedicated MRI brand, Ezra/Function is the aggressive value challenger, and Human Longevity is the executive-health package for buyers who want genomics, imaging and physician review in one day.
Worth considering for high-risk, high-agency buyers with a doctor who owns the follow-up. Weak for healthy low-risk buyers expecting a normal scan to mean future safety.
We went in 2026: a broad but standard panel (full lipids, HbA1c, a white-cell differential, hs-CRP), strong skin mapping and real doctor time, but no ApoB. A sensor, skin, cardiovascular and blood-marker baseline with a doctor consult, not a whole-body MRI.
Now sold mainly as membership: Core ($1,199, 45-min focused scan + blood panel), Comprehensive ($2,499, 60-min whole-body scan + panel + 6-month follow-up labs) or Executive ($3,999, $4,499 in NYC/LA/Chicago, adds brain and heart imaging). Better if MRI plus annual rescanning is the product you actually want.
The base MRI Scan is $899 for Function members, $999 regular, 22 minutes, and explicitly excludes chest, lungs, heart, breasts, spine and intestines. Read the exclusion list before assuming "whole body" means whole body; pay for the $1,499 spine tier or $3,999 skeletal/neurological tier only if those are the organs you actually want checked.
Whole-body MRI, genome sequencing, 120+ biomarkers and physician review. Expensive, but coherent for the executive-health buyer.
The American College of Radiology does not believe there is enough evidence to recommend total-body screening for people with no symptoms, risk factors or family history suggesting serious disease. Its 2023 statement is direct: no documented evidence that total-body screening is cost-efficient or effective in prolonging life, and a real risk that non-specific findings snowball into unnecessary follow-up testing and expense.
That does not make every scan irrational. It means the scan is not a proven population-health intervention, and the odds of what it actually finds are worth pricing before you book.
A 2025 systematic review and meta-analysis in European Radiology pooled 9,024 asymptomatic people across 10 studies and found a confirmed-cancer detection rate of 1.57% (95% CI 1.22-2.03%), meaning roughly 1 in 64 scanned. That is the number the marketing implies is much higher.
An earlier systematic review in the Journal of Magnetic Resonance Imaging (Kwee and Kwee, 2019), covering 5,373 asymptomatic subjects across 12 studies, found 13.4% had a critical incidental finding and 13.9% an indeterminate one, a combined 32.1%. Of those reported critical or indeterminate findings, 16.0% were later confirmed false positives, and the authors could find verification data for only 12.6% of them.
Put the two numbers side by side: you are roughly 20 times more likely to leave with an ambiguous or falsely alarming finding than with a confirmed cancer diagnosis. The 2019 review's own conclusion is blunt - it recommends against offering whole-body MRI for preventive screening to asymptomatic subjects outside a research setting. The scan is the start of the decision tree, not the end, and the branch you are most likely to land on is the ambiguous one, not the decisive one.
Choose Neko if you want a fast baseline and doctor conversation without MRI-level cost. Choose Prenuvo if the core desire is MRI and you accept the membership price and annual rescanning cadence. Choose Ezra/Function only after checking which organs the tier you are paying for actually covers - the base scan skips chest, lungs, heart, breasts and spine. Choose Human Longevity if you want a high-touch executive day with genomics and physician review.
The best question before booking is: who owns the follow-up if something is abnormal? If the answer is "my already-overloaded GP", count that burden, and the roughly one-in-three odds of triggering it, as part of the price.
Skip if you are healthy, low-risk, prone to health anxiety and have no clinician ready to interpret ambiguous findings. With a documented one-in-three chance of a critical or indeterminate finding, that clinician relationship is not optional paperwork - it is most of what you are paying for.
Also skip if the marketing makes you think a normal scan means you are safe. False negatives are part of screening too, and a clean report at 1.57% detection is reassurance, not proof.
No. They may find important disease in some people, but there is no documented evidence that total-body screening is cost-efficient or effective in prolonging life for asymptomatic average-risk people, per the American College of Radiology.
Low. A 2025 systematic review pooling 9,024 asymptomatic people found a confirmed-cancer detection rate of 1.57% (about 1 in 64). Treat any advertised detection story as the exception, not the expectation.
Often. A systematic review of 5,373 asymptomatic subjects found 32.1% had a critical or indeterminate incidental finding, and 16.0% of those reported findings were later confirmed false positives. Budget for a follow-up visit, not just the scan.
No. Neko is a sensor, skin, cardiovascular and blood-marker visit with a doctor consult. Prenuvo is a whole-body MRI provider, now sold mainly as an annual membership.
Not at the base price. The $899-999 MRI Scan explicitly excludes chest, lungs, heart, breasts, spine and intestines. Spine coverage requires the $1,499 tier; skeletal and neurological screening requires the $3,999 tier.
By David Persson · Updated 2026-07-13 · Corrections: hi@agewell.guide
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.